0001209191-18-021991.txt : 20180328
0001209191-18-021991.hdr.sgml : 20180328
20180328201008
ACCESSION NUMBER: 0001209191-18-021991
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180327
FILED AS OF DATE: 20180328
DATE AS OF CHANGE: 20180328
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clark Mitchall G.
CENTRAL INDEX KEY: 0001612094
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36548
FILM NUMBER: 18720262
MAIL ADDRESS:
STREET 1: C/O ATARA BIOTHERAPEUTICS, INC.
STREET 2: 3260 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001604464
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 460920988
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-278-8930
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-27
0
0001604464
Atara Biotherapeutics, Inc.
ATRA
0001612094
Clark Mitchall G.
611 GATEWAY BOULEVARD
SUITE 900
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
EVP & Chief R & QA Officer
Common Stock
2018-03-27
4
M
0
28848
25.15
A
212368
D
Common Stock
2018-03-27
4
M
0
32500
22.72
A
244868
D
Common Stock
2018-03-27
4
M
0
11406
11.00
A
256274
D
Common Stock
2018-03-27
4
S
0
22794
36.43
D
233480
D
Common Stock
2018-03-27
4
S
0
31356
37.10
D
202124
D
Common Stock
2018-03-27
4
S
0
29980
38.23
D
172144
D
Common Stock
2018-03-27
4
S
0
2170
39.53
D
169974
D
Common Stock
2018-03-27
4
S
0
2800
40.40
D
167174
D
Common Stock
2018-03-27
4
S
0
11103
41.10
D
156071
D
Employee Stock Option (Right to Buy)
25.15
2018-03-27
4
M
0
28848
0.00
D
2022-01-16
Common Stock
28848
11194
D
Employee Stock Option (Right to Buy)
22.72
2018-03-27
4
M
0
32500
0.00
D
2022-12-17
Common Stock
32500
32500
D
Employee Stock Option (Right to Buy)
11.00
2018-03-27
4
M
0
11406
0.00
D
2021-10-14
Common Stock
11406
3125
D
Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.70 to $36.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.75 to $37.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.80 to $38.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.85 to $39.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.00 to $40.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
1/48th of the shares subject to the stock option vest and become exercisable each month following January 16, 2015.
1/48th of the shares subject to the stock option vest and become exercisable each month following December 17, 2015.
1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014.
/s/ David Tucker, Attorney-in-Fact for Mitchall G. Clark
2018-03-28